Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | JAK1 | P23458 | 1/20 | 0.46 |
| ▸ | JAK3 | P52333 | 1/20 | 0.46 |
| ▸ | HRH4 | Q9H3N8 | 16/20 | 0.45 |
| ▸ | NPY1R | P25929 | 1/20 | 0.43 |
| ▸ | GCGR | P47871 | 2/20 | 0.43 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.41 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.41 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL604535 | 0.93 | JAK2 (0.46) | JAK2JAK1JAK3HRH4NPY1R | |
| SCHEMBL602373 | 0.93 | HRH4 (0.47) | JAK2JAK1JAK3HRH4NPY1R | |
| SCHEMBL12253119 | 0.89 | HRH4 (0.48) | JAK2JAK1HRH4NPY1RGCGR | |
| SCHEMBL602374 | 0.88 | HRH4 (0.45) | JAK2JAK1JAK3HRH4GCGR | |
| SCHEMBL602471 | 0.86 | HRH4 (0.47) | JAK2JAK1JAK3HRH4NPY1R | |
| SCHEMBL603438 | 0.84 | GCGR (0.46) | HRH4NPY1RGCGRMAPK13MAPK12 | |
| SCHEMBL605806 | 0.84 | JAK1 (0.44) | JAK2JAK1HRH4NPY1RGCGR | |
| SCHEMBL604458 | 0.84 | HRH4 (0.42) | JAK2JAK1JAK3HRH4MAPK11 | |
| SCHEMBL605754 | 0.83 | GCGR (0.43) | HRH4GCGRMAPK13MAPK12MAPK11 | |
| SCHEMBL2166887 | 0.83 | HRH4 (0.47) | JAK2JAK1JAK3HRH4NPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1737297-B1 | IMIDAZOLE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2012-12-19 | — | — | EP | claimed |
| US-8017639-B2 | Imidazole compounds | JANSSEN PHARMACEUTICA NV (BE) | 2011-09-13 | — | — | US | claimed |
| US-20100261898-A1 | IMIDAZOLE COMPOUNDS | BUZARD DANIEL J | 2010-10-14 | — | — | US | claimed |
| EP-1737297-A4 | IMIDAZOLE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2009-07-15 | — | — | EP | claimed |
| US-20070173513-A1 | Imidazole compounds | JANSSEN PHARMACEUTICA, N.V. | 2007-07-26 | — | — | US | claimed |
| EP-1737297-A2 | IMIDAZOLE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-01-03 | — | — | EP | claimed |
| US-20050261309-A1 | Imidazole compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-11-24 | — | — | US | claimed |
| WO-2005092066-A2 | IMIDAZOLE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-10-06 | — | — | WO | claimed |
| US-10195195-B2 | Selective histamine H4 receptor antagonists for the treatment of vestibular disorders | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2019-02-05 | — | — | US | disclosed |
| EP-3378476-A1 | H4 RECEPTOR INHIBITORS FOR TREATING TINNITUS | Sensorion (FR) | 2018-09-26 | — | — | EP | disclosed |
| US-9688989-B2 | H4 receptor inhibitors for treating tinnitus | SENSORION (FR) | 2017-06-27 | — | — | US | disclosed |
| US-20170056397-A1 | SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2017-03-02 | — | — | US | disclosed |
| EP-3130376-A1 | SELECTIVE HISTAMINE H4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF VESTIBULAR DISORDERS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2017-02-15 | — | — | EP | disclosed |
| US-9526725-B2 | Selective histamine H4 receptor antagonists for the treatment of vestibular disorders | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2016-12-27 | — | — | US | disclosed |
| US-20070149541-A1 | Imidazole compounds | JANSSEN PHARMACEUTICA, N.V. | 2007-06-28 | — | — | US | disclosed |
| US-20070149541-A1 | Imidazole compounds | JANSSEN PHARMACEUTICA, N.V. | 2007-06-28 | — | — | US | disclosed |
| US-20070149541-A1 | Imidazole compounds | JANSSEN PHARMACEUTICA, N.V. | 2007-06-28 | — | — | US | disclosed |
| EP-1737297-A2 | IMIDAZOLE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-01-03 | — | — | EP | disclosed |
| US-20050261309-A1 | Imidazole compounds | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-11-24 | — | — | US | disclosed |
| WO-2005092066-A2 | IMIDAZOLE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261898-A1 | IMIDAZOLE COMPOUNDS | HRH4, HRH3, HRH2 | JAK2 453/4885JAK1 1700/4885JAK3 1449/4885 |
| US-20070149541-A1 | Imidazole compounds | HRH4, HRH3, HRH2 | JAK2 453/4885JAK1 1700/4885JAK3 1449/4885 |
| US-20070173513-A1 | Imidazole compounds | HRH4, HRH3, HRH2 | JAK2 453/4885JAK1 1700/4885JAK3 1449/4885 |
| US-20050261309-A1 | Imidazole compounds | HRH4, HRH3, HRH2 | JAK2 453/4885JAK1 1700/4885JAK3 1449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.